Tariffs are an overhang on pharma sector, but we will comeback, says Novartis CEO Vas Narasimhan

Welcome back to Money Movers. Take a look at shares of Novartis down nearly 3% despite posting a beat on the top and bottom lines. Hiking full year guidance upping the buyback.Swiss pharma company saying its build up of U.S. Inventories will help mitigate the impact of tariffs this year. Joining us to break down the quarters, Novartis CEO Vas Narasimhan. It's great to see you again, boss.Welcome back. >> Thanks, Sarah. Great to be with you.>> I mean, there's so much going on in your sector and there's a ...